A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination with Anticancer Agents Including Pembrolizumab in Adult Participants with Selected Advanced Solid Tumors
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Enrolling: Male and Female Patients
IRB Number: AAAS1446
U.S. Govt. ID: NCT03681951
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: GSK3145095 inhibits receptor interacting protein 1 (RIP1) which may affect your immune systems response (ability to fight) to your cancer. GSK3145095 is not yet FDA approved for use in humans. This study is the first time that GSK3145095 is being given to people. This research study is being done to learn more about your cancer and if GSK3145095 can improve your cancer/make you feel better. You are expected to stay on study treatment for up to 2 years. This study may include up to 220 study participants. We also would like to answer the following question such as is GSK3145095 safe, how well does GSK3145095 work to treat people with your cancer and related conditions, what dose(s) of GSK3145095 works best and how does your body break down GSK3145095.
This study is closed
Gulam Manji, MD, PhD
Do You Qualify?
Are you age 18 or older? Yes No
Are you willing to provide fresh tissues? Yes No
Have you been diagnosed with pancreatic adenocarcioma, non-small cell lung cancer, triple negative breast cancer, or melanoma? Yes No
Do you have life expectancy of at least 12 weeks? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator